Detection of Hepatocellular Carcinoma (HCC) With Octanoate Breath ID Test Compared to MRI
Status:
Terminated
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
The Exalenz clinical investigation is a multicenter, non-randomized, study of the
¹³C-Octanoate Breath Test (OBT). The present study is a feasibility trial, which aims to
evaluate the capability of the OBT measurement to differentiate between presence and absence
of HCC determined by Magnetic Resonance Imaging (MRI) in patients with chronic liver disease.
Phase:
Phase 2
Details
Lead Sponsor:
Exalenz Bioscience LTD.
Collaborators:
Hadassah Medical Organization Henry Ford Health System Medical University of South Carolina Northwestern University Toronto General Hospital